Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease

Journal of the American Society of Nephrology

Volumn 16, Issue 8, 2005, Pages 2412-2420

  Schwartz, Elissa J ^a,c   Szczech, Lynda A ^b   Ross, Michael J ^a   Klotman, Mary E ^a   Winston, Jonathan A ^a   Klotman, Paul E ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DISEASE COURSE; EPIDEMIC; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; KIDNEY FAILURE; MATHEMATICAL MODEL; NEGRO; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; UNITED STATES;

EID: 28444460367     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005040340     Document Type: Article

References (39)

1. Ross MJ, Klotman PE, Winston JA: HIV-associated nephropathy: Case study and review of the literature. AIDS Patient Care STDS 14: 637-645, 2000
2. Ross MJ, Klotman PE: Recent progress in HIV-associated nephropathy. J Am Soc Nephrol 13: 2997-3004, 2002
3. Ross MJ, Klotman PE: HIV-associated nephropathy. AIDS 18: 1089-1099, 2004
4. Winston JA, Burns GC, Klotman PE: The human immunodeficiency virus (HIV) epidemic and HIV-associated nephropathy. Semin Nephrol 18: 373-377, 1998
5. Smith MC, Austen JL, Carey JT, Emancipator SN, Herbener T, Gripshover B, Mbanefo C, Phinney M, Rahman M, Salata RA, Weigel K, Kalayjian RC: Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. Am J Med 101: 41-48, 1996
6. Burns GC, Paul SK, Toth IR, Sivak SL: Effect of angiotensin-converting enzyme inhibition in HIV-associated nephropathy. J Am Soc Nephrol 8: 1140-1146, 1997
7. Michel C, Dosquet P, Ronco P, Mougenot B, Viron B, Mignon F: Nephropathy associated with infection by human immunodeficiency virus: A report on 11 cases including 6 treated with zidovudine. Nephron 62: 434-440, 1992
8. Kimmel PL, Mishkin GJ, Umana WO: Captopril and renal survival in patients with human immunodeficiency virus nephropathy. Am J Kidney Dis 28: 202-208, 1996
9. Ifudu O, Rao TK, Tan CC, Fleischman H, Chirgwin K, Friedman EA: Zidovudine is beneficial in human immunodeficiency virus associated nephropathy. Am J Nephrol 15: 217-221, 1995
10. Wali RK, Drachenberg CI, Papadimitriou JC, Keay S, Ramos E: HIV-1-associated nephropathy and response to highly-active antiretroviral therapy. Lancet 352: 783-784, 1998
11. Dellow E, Unwin R, Miller R, Williams I, Griffiths M: Protease inhibitor therapy for HIV infection: The effect on HIV-associated nephrotic syndrome. Nephrol Dial Transplant 14: 744-747, 1999
12. Szczech LA, Edwards LJ, Sanders LL, van der Horst C, Bartlett JA, Heald AE, Svetkey LP: Protease inhibitors are associated with a slowed progression of HIV-related renal diseases. Clin Nephrol 57: 336-341, 2002
13. Rao TKS, Friedman EA: Declining incidence of end-stage renal disease (ESRD) complicating human immunodeficiency virus (HIV) infection. ASAIO J 46: 214, 2000
14. Izzedine H, Tostivint I, Francois M, Deray G: Is antiretroviral treatment beneficial on HIV nephropathy? Clin Nephrol 55: E8-E9, 2001
15. Eggers PW, Kimmel PL: Is there an epidemic of HIV infection in the US ESRD program? J Am Soc Nephrol 15: 2477-2485, 2004
16. HIV/AIDS Surveillance Report. Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Atlanta, 1997
17. HIV/AIDS Surveillance Report. Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Atlanta, 1998
18. HIV/AIDS Surveillance Report. Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Atlanta, 2001
19. HIV/AIDS Surveillance Report. Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Atlanta, 2002
20. US Renal Data System: USRDS 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2002
21. Schwartz EJ, Klotman PE: Pathogenesis of human immunodeficiency virus (HIV)-associated nephropathy. Semin Nephrol 18: 436-445, 1998
22. Szczech LA, Gupta SK, Habash R, Guasch A, Kalayjian R, Appel R, Fields TA, Svetkey LP, Flanagan KH, Klotman PE, Winston JA: The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 66: 1145-1152, 2004
23. Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD: Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: A 12-year cohort study. AIDS 18: 541-546, 2004
24. He JC, Husain M, Sunamoto M, D'Agati VD, Klotman ME, Iyengar R, Klotman PE: Nef stimulates proliferation of glomerular podocytes through activation of Src-dependent Stat3 and MAPK1,2 pathways. J Clin Invest 114: 643-651, 2004
25. Husain M, Gusella GL, Klotman ME, Gelman IH, Ross MD, Schwartz EJ, Cara A, Klotman PE: HIV-1 Nef induces proliferation and anchorage-independent growth in podocytes. J Am Soc Nephrol 13: 1806-1815, 2002
26. Schwartz EJ, Cara A, Snoeck H, Ross MD, Sunamoto M, Reiser J, Mundel P, Klotman PE: Human immunodeficiency virus-1 induces loss of contact inhibition in podocytes. J Am Soc Nephrol 12: 1677-1684, 2001
27. Sunamoto M, Husain M, He JC, Schwartz EJ, Klotman PE: Critical role for Nef in HIV-1-induced podocyte dedifferentiation. Kidney Int 64: 1695-1701, 2003
28. Bruggeman LA, Ross MD, Tanji N, Cara A, Dikman S, Gordon RE, Burns GC, D'Agati VD, Winston JA, Klotman ME, Klotman PE: Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol 11: 2079-2087, 2000
29. Bruggeman LA, Dikman S, Meng C, Quaggin SE, Coffman TM, Klotman PE: Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression. J Clin Invest 100: 84-92, 1997
30. Barisoni L, Bruggeman LA, Mundel P, D'Agati VD, Klotman PE: HIV-1 induces renal epithelial dedifferentiation in a transgenic model of HIV-associated nephropathy. Kidney Int 58: 173-181, 2000
31. Cunningham WE, Markson LE, Andersen RM, Crystal SH, Fleishman JA, Golin C, Gifford A, Liu HH, Nakazono TT, Morton S, Bozzette SA, Shapiro MF, Wenger NS: Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States. HCSUS Consortium. HIV Cost and Services Utilization. J Acquir Immune Defic Syndr 25: 115-123, 2000
32. Winston JA, Klotman ME, Klotman PE: HIV-associated nephropathy is a late, not early, manifestation of HIV-1 infection. Kidney Int 55: 1036-1040, 1999
33. Szczech LA, Klassen P, Fox K, van der Horst C, Bartlett J, Svetkey LP: Predictors of proteinuria and renal failure among patients with HIV infection [Abstract]. J Am Soc Nephrol 11: 98A, 2000
34. Laradi A, Mallet A, Beaufils H, Allouache M, Martinez F: HIV-associated nephropathy: Outcome and prognosis factors. Groupe d' Etudesqqnephrologiquesqq d'Ile de France. J Am Soc Nephrol 9: 2327-2335, 1998
35. Winston JA, Bruggeman LA, Ross MD, Jacobson J, Ross L, D'Agati VD, Klotman PE, Klotman ME: Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med 344: 1979-1984, 2001
36. Eustace JA, Nuermberger E, Choi M, Scheel PJ Jr, Moore R, Briggs WA: Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int 58: 1253-1260, 2000
37. Szczech LA, Hoover DR, Feldman JG, Cohen MH, Gange SJ, Gooze L, Rubin NR, Young MA, Cai X, Shi Q, Gao W, Anastos K: Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis 39: 1199-1206, 2004
38. Gardner LI, Klein RS, Szczech LA, Phelps RM, Tashima K, Rompalo AM, Schuman P, Sadek RF, Tong TC, Greenberg A, Holmberg SD: Rates and risk factors for condition-specific hospitalizations in HIV-infected and uninfected women. J Acquir Immune Defic Syndr 34: 320-330, 2003
39. Gardner LI, Holmberg SD, Williamson JM, Szczech LA, Carpenter CC, Rompalo AM, Schuman P, Klein RS: Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women. J Acquir Immune Defic Syndr 32: 203-209, 2003 2421-2430